Differentially Expressed Downstream Genes in Cells with Normal or Mutated p53

Oncology Research

Volumn 13, Issue 6-10, 2002, Pages 429-436

  Xu, Hao ^a   El Gewely, M Raafat ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Alternative splicing; Differential display; Expression profile; Mutation; p53; Transient expression

Indexed keywords

PROTEIN P53;

CANCER DIAGNOSIS; CANCER INVASION; CARCINOGENESIS; CARCINOGENICITY; CONFERENCE PAPER; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WILD TYPE; ALTERNATIVE RNA SPLICING; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MUTATION; OSTEOSARCOMA; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION;

ALTERNATIVE SPLICING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; OSTEOSARCOMA; SEQUENCE ANALYSIS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED;

EID: 0842348964     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504003108748456     Document Type: Conference Paper

References (16)

1. Cadwell, C.; Zambetti, G. P. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15-30; 2001.
2. Xu, H.; El-Gewely, M. R. p53-responsive genes and the potential for cancer diagnostics and therapeutics development. In: El-Gewely, M. R., ed. Biotechnology annual review. Amsterdam: Elsevier Science Publishers B.V.; 2001:131-164.
3. Loging, W. T.; Reisman, D. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. Oncogene 18:7608-7615; 1999.
4. Xu, H.; El-Gewely, M. R. p53 mutants related cancers: A survey of IARC p53 somatic mutation database. (in preparation).
5. van Oijen, M. G. C. T.; Slootweg, P. J. Gain-of-function mutations in the tumor suppressor gene p53. Clin. Cancer Res. 6:2138-2145; 2000.
6. Sial, A.; Rotter, V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res. 60:6788-6793; 2000.
7. Liang, P.; Pardee, A. B. Differential display of eucaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967-971; 1992.
8. Fu, Y. Detection of differentially expressed genes in cancer using differential display. Methods Mol. Med. 68:179-193; 2002.
9. Vernet, G. DNA-chip technology and infectious diseases. Virus Res. 82:65-71; 2002.
10. Lilley, K. S.; Razzaq, A.; Dupree, P. Two-dimensional gel electrophoresis: Recent advances in sample preparation, detection and quantitation. Curr. Opin. Chem. Biol. 6:46-50; 2002.
11. Salomonsen, L. J.; Xu, H.; Hansen, A.; Karlsen, J.; El-Gewely, M. R. Modified differential display with double-stranded cDNA, a more efficient approach. Genome Lett. 1(3):140-146; 2002.
12. Chen, P. L.; Chen, Y. M.; Bookstein, R.; Lee, W. H. Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1580; 1990.
13. Miller, C. W.; Chumakov, A.; Said, J.; Chen, D. L.; Aslo, A.; Koeffler, H. P. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8:1815-1824; 1993.
14. Hermeking, H.; Lengauer, C.; Polyak, K.; He, T-C.; Zhang, L.; Thiagalingam, S.; Kinzler, K. W.; Vogelstein, B.; The Johns Hopkins Oncology Center 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1:3-11; 1997.
15. Zhang, H.; Somasundaram, K.; Peng, Y.; Tian, H.; Zhang, H.; Bi, D.; Weber, B. L.; El-Deiry, W. S. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16:1713-1721; 1998.
16. Aprelikova, O.; Pace, A. J.; Fang, B. BRCA1 is a selective co-activator of 14-3-3σ gene transcription in mouse embryonic stem cells. J. Biol. Chem. 276:25647-25650; 2001.